|About this Abstract
||2017 TMS Annual Meeting & Exhibition
||Bio-Nano Interfaces and Engineering Applications
||Silica Nanostructured Platform for Affinity Capture of Tumor-Derived Exosomes
||Parissa Ziaei, Jonathan J. Geruntho, Oscar G. Marin-Flores, Clifford E. Berkman, M. Grant Norton
|On-Site Speaker (Planned)
Developing effective and high-throughput selective capture technology for positive prostate-specific membrane antigen (PSMA+) exosomes is critical for early diagnostic and prognostic evaluation of prostate cancer treatment. It is known that the prostate tumor enzyme-biomarker, prostate-specific membrane antigen (PSMA) is highly enriched in exosomes excreted by PSMA+ prostate cancer cells. Using PSMA+ LNCaP cells, the secreted exosomes were collected and isolated from the cultured media. A novel biofunctionalized silica nanostructure was designed to selectivity capture tumor-derived exosomes through the interaction of the TG97 ligand with PSMA on the exosomes. The biocinchonic acid (BCA) assay demonstrates both specific and non-specific exosome capture and high capture efficiency for the ligand-activated silica nanostructures.
||Planned: Supplemental Proceedings volume